Novartis AG SF-Anl. 2024(27)
Type of financial instrument
Corporate Bond
Sub-Type
Health Care
Yield
0.28
Yield spread Bundesanleihe
-2.4551
Tradable for private investors
Yes
Minimum amount tradeable unit
5,000.00
Maturity
18/06/2027
Interest Rate
1.60 %
Currency
Swiss Franc
Facts & figures
Price data
| TRADE PLATFORM | ||
| LAST PRICE / YIELD | 101.171 G / 0.28 | 0 Units |
| PRICE DETERMINATION TIME | 07/27/2026 / 09:47:29 PM | |
| DAILY VOLUME (NOMINAL) | 0 | |
| YIELD SPREAD | -2.4551 | |
| FIXINGPRICE | - | |
| DAILY HIGH / LOW | 101.171 | 101.12 |
| PREV. DAY'S PRICE | 101.143 | (07/24) |
| CHANGE DAY BEFORE | +0.03 | 0.03 % |
| 52 WEEK HIGH / LOW | 102.55 (08/05) | 101.09 (07/16) |
Master Data
| WKN | A3LZ2Q |
| ISIN | CH1353257806 |
| SYMBOL | - |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Corporate Bond |
| SUB-TYPE | Health Care |
| ISSUER | Novartis AG |
| S&P RATING | Please log in to view this field |
| (TRADING) SEGMENT / TICKS | -/ - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| INTEREST RATE | 1.60 % |
| INTEREST RUN FROM | 18/06/2024 |
| NEXT INTEREST PAYMENT | 18/06/2027 |
| UNIT INTEREST FROM NOMINAL AMMOUNT | 0.182 % |
| TRADING CURRENCY / NOTATION | Swiss Franc/ Percent |
| NOMINAL CURRENCY | Swiss Franc |
| SETTLEMENT CURRENCY | Euro |
| QUOTATION | Continuous trading |
| ISSUING VOLUME | 650.00 Mil. |
| MINIMUM AMOUNT TRADEABLE UNIT | 5,000.00 |
| SMALLEST TRADEABLE UNIT | 5,000.00 |
| MATURITY | 18/06/2027 |
| MARKET MAKER | - |
| STEP UP/ DOWN WHEN RATING CHANGES | No |
| STEP UP FIXED AT ISSUE | No |
| STEP DOWN FIXED AT ISSUE | No |
| BOND CALLABLE BY THE ISSUER | No |
| BOND IS SUBORDINATED | No |
Description
Local currency bond: CHF.
Tradability Information
Please log in to see the tradability information for this stock.Not registered yet? Create your free account here.
Company profile
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.